M&A / Deals UCB to purchase Neurona and NRTX-1001 for $1.15bn Pharmaceutical Business ReviewThe deal value comprises an upfront payment of up to $650m and up to $500m in future milestones.M&A / DealsNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Business Review The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. M&A / DealsNeuroscienceRead full story Post navigation Previous: MSD secures EC approval for Enflonsia to prevent infant RSV infectionNext: Trump backs psychedelics for mental health in new executive order Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026